Vice President - Oncology Clinical Development, Disease Area Head- Hematology

GSK•Upper Providence, PA

7d•$340,500 - $567,500•Hybrid

About The Position

GSK is seeking to appoint a VP, Oncology Clinical Development Disease Area Head, reporting to the SVP, Head of Oncology Clinical Development. With accountability for the planning and implementation of the clinical development strategy across the Hematology portfolio, you will lead and contribute to strategic clinical positioning of early- and late-phase assets across their life-cycle with a cross-functional matrix team, at a pivotal moment for the organization as it sharpens its focus on pace, performance, portfolio delivery and bringing differentiated medicines to patients. This role requires an experienced, cross-matrix senior leader capable of implementing and executing an integrated clinical strategy in support of the successful clinical development, translational research, regulatory filing and initial market launch of a growing portfolio of innovative and transformational Oncology therapies.

Requirements

Medical degree with board certification or eligibility in oncology
At least 10 years clinical development experience leading global clinical development programs in hematology and oncology in the pharmaceutical industry, academia, or combined.
Senior clinical and scientific leadership in early- and late-phase oncology drug development, including FTIH through registrational trials and launch readiness.
Proven track record designing and delivering late-phase clinical trials and regulatory submissions.
Experience leading geographically dispersed teams and complex multi-stakeholder programs.

Nice To Haves

Clinical background in hematologic malignancies or hematology subspecialty.
Strong ability to translate science and translational insight into differentiated clinical development strategies across disease areas and portfolios.
Proven capability to operate as an enterprise drug developer at portfolio level, balancing priorities, risk, and resources while maintaining asset-level rigor and accountability.
Credibility and effectiveness representing Clinical Development at senior governance forums, with strong executive presence and influence.
Advanced cross-functional and matrix leadership skills, with a natural connector mindset across research, development, medical, commercial, and precision medicine partners.
Openness to and fluency with innovative development approaches (e.g., AI/ML, novel trial designs, external and real-world data) where they add value.
Demonstrated strength in leading and developing senior clinical leaders, with accountability for performance, succession planning, and capability building.
Commitment to fostering a culture of scientific excellence, empowerment, inclusion, and continuous improvement in a complex global environment

Responsibilities

Accountable for end-to-end clinical development of oncology assets from first-in-human (FTIH) studies through proof-of-concept studies, registrational trials, regulatory approval, and initial market launch, ensuring scientific rigor, speed, and quality of execution.
Shape and drive the scientific and clinical development strategy for assigned disease areas and assets, aligned with Oncology Tumor Team strategy and broader Oncology portfolio priorities.
Ensure deep integration of clinical, and disease-area expertise into preclinical and translational research activities to optimize asset positioning, biomarker strategy, and development strategy and decisions.
Evaluate, champion, and enable the use of novel approaches (e.g., AI/ML, innovative trial designs, external and real-world data sources) where they add clear scientific, operational, or decision-making value to clinical development.
Provide program-level oversight and leadership, while ensuring connectedness both cross functionally and across assets, maintaining visibility to progress, risks, dependencies, and trade-offs across the Oncology portfolio.
Serve as the senior clinical representative at key governance forums for assigned programs, ensuring strong clinical leadership, continuity, and high-quality decision-making.
Represent the Oncology Clinical Development organization internally and externally, including presenting at high-impact forums such as congress all-hands, senior leadership reviews, and advisory boards.
Lead scientific advisory boards and other external engagements to inform asset strategy, competitive positioning, and portfolio decisions, incorporating emerging science and external expert insight.
Co-lead asset development with matrix leadership partners, driving alignment across research, development, and commercialization planning, and ensuring cohesive execution against shared objectives.
Lead with an enterprise mindset: Act as a senior connector across functions, partnering closely with Oncology Research, Translational Research, Translational Medicine, Medical Affairs, Global Product Strategy, and Competitive Intelligence to drive integrated development and lifecycle planning.
Build and sustain strong internal and external partnerships to accelerate decision-making, resolve complexity, and optimize development outcomes in a matrixed environment.
Line-manage and mentor Clinical Development Leads, Clinical Science Program Leads, Medical Directors, and Clinical Scientists, with clear accountability for performance, development, engagement, and succession planning.
Provide clarity on roles, expectations, and career paths within Oncology Clinical Development, contributing to role definitions, capability frameworks, and targeted training strategies.
Foster a culture of empowerment, enterprise-level drug development, scientific excellence, inclusion, and collaboration, aligned with OneOncology values, while modeling strong, visible leadership.
Actively remove organizational barriers and enable teams to operate effectively and autonomously within a complex, global matrix environment.
Contribute to the establishment and continuous evolution of clinical development standards, processes, and best practices across Oncology, ensuring consistency, quality, and regulatory readiness.
Ensure timely access to relevant external scientific and competitive intelligence (e.g., congress data, emerging science, competitor activity) to inform clinical development decisions and portfolio strategy.